Retatrutide:

Metabolic regulation can be imagined as a control room rather than a single switch. GLP-1 represents one control, GIP another, and glucagon a third. Earlier generations of incretin-based therapies learned to influence one of these systems effectively, and later therapies began coordinating two. Retatrutide extends the idea further by attempting to manipulate three related but distinct metabolic pathways within a single molecule.

This does not mean every receptor contributes equally to every clinical effect, nor does it mean researchers have already separated the role of each receptor in humans. Instead, retatrutide changes the experimental question. Rather than asking only what happens when GLP-1 signalling is enhanced, researchers can study what occurs when appetite regulation, incretin signalling and glucagon-related energy metabolism are altered simultaneously.

The unusually large clinical effects suggest that this three-receptor approach is biologically important, but understanding exactly why remains an active area of research.

Retatrutide should not be understood as a compound that simply “burns fat.” Its effects emerge from coordinated hormone-receptor signalling that influences appetite, glucose regulation, nutrient handling and energy metabolism.

GLP-1 and GIP pathways can influence food intake and glycemic control, while glucagon-receptor activity introduces another metabolic signal with potential effects on hepatic metabolism, substrate use and energy expenditure. Preclinical studies support the idea that glucagon-receptor activation contributes to increased energy expenditure with retatrutide, but the large human obesity trials were designed primarily to measure clinical outcomes rather than to determine exactly how many additional calories were expended because of that mechanism.

This means researchers can say with confidence that body weight, glucose regulation, liver fat and several other metabolic markers changed. They are still working to determine exactly how those outcomes were produced.

THREE THINGS RESEARCH HAS DEMONSTRATED

1. Retatrutide Can Produce Very Large Reductions in Body Weight

The strongest retatrutide evidence concerns body weight. In the landmark Phase 2 randomized, double-blind, placebo-controlled obesity trial published in the New England Journal of Medicine, researchers enrolled 338 adults with obesity, or overweight accompanied by at least one weight-related condition.

At 48 weeks, the average weight changes were dose dependent. Participants receiving 1 mg lost an average of 8.7% of their starting body weight, while those receiving 4 mg lost 17.1%, those receiving 8 mg lost 22.8%, and those receiving 12 mg lost 24.2%. The placebo group lost 2.1%. At the 12 mg dose, 83% of participants reached at least 15% weight reduction, while 26% reached at least 30%. Importantly, the average weight-loss curve had not clearly plateaued by the end of the 48-week treatment period. [1]

That finding raised an obvious question: what would happen if treatment continued longer?

In May 2026, Eli Lilly reported topline results from the much larger Phase 3 TRIUMPH-1 trial. Participants receiving 12 mg retatrutide reportedly lost an average of 70.3 pounds, or 28.3% of initial body weight, over 80 weeks. The average baseline weight was approximately 248.5 pounds, and 45.3% of participants in the 12 mg group reached at least 30% weight reduction. In a prespecified extension population with a baseline BMI of at least 35, those continuing treatment to 104 weeks reportedly reached an average reduction of approximately 30.3%. [2]

These Phase 3 findings are important, but they should be interpreted differently from the Phase 2 data. The Phase 2 obesity trial is peer reviewed and fully published. The May 2026 Phase 3 figures are currently company-reported topline results and should remain labelled as such until the complete dataset is published and independently scrutinized.

Still, the overall trajectory is noteworthy. The strong signal first observed in Phase 2 persisted when retatrutide moved into a much larger Phase 3 population, and the average reduction increased further with longer treatment.

HUMAN STORY

The numbers become easier to understand when translated into a typical trial participant. Someone entering the study at roughly 248 pounds and experiencing the group-average 28.3% reduction would be approximately 70 pounds lighter after 80 weeks.

That does not mean every participant experienced the same result. Clinical averages include people who respond strongly, people who respond modestly, people who discontinue and people who experience side effects. But the scale of the average change helps explain why retatrutide has attracted so much scientific and public attention.

2. Retatrutide Can Dramatically Reduce Liver Fat in Selected Study Participants

One of the most interesting retatrutide studies did not focus primarily on body weight. Researchers selected 98 participants from the Phase 2 obesity trial who had metabolic dysfunction-associated steatotic liver disease, or MASLD, with at least 10% liver fat. They then used MRI proton density fat fraction, or MRI-PDFF, to quantify changes in hepatic fat.

At 24 weeks, average relative liver-fat reduction reached 42.9% in the 1 mg group, 57.0% with 4 mg, 81.4% with 8 mg and 82.4% with 12 mg. The placebo group showed essentially no improvement, changing by 0.3%. At the two highest doses, more than 85% of participants reached liver-fat levels below 5% by week 24. [3]

The timing of the change was especially interesting. Most of the reduction in liver fat occurred during the first 24 weeks, while body weight continued to decline afterward. This suggests that different tissues and energy stores were not simply shrinking in parallel. Liver fat appeared to fall rapidly and approach a physiological floor while total body weight continued to change.

Researchers also observed substantial reductions in visceral adipose tissue. These findings suggest that some of retatrutide’s most biologically interesting effects may occur inside organs and metabolic compartments rather than simply appearing on a scale.

The study does have important limitations. It involved only 98 participants, fewer participants had usable imaging at later time points, and MRI-PDFF measures liver fat rather than every pathological feature of liver disease. The study did not use liver biopsy histology to prove reversal of fibrosis or complete resolution of MASLD.

The evidence therefore supports the statement that retatrutide produced very large reductions in measured liver fat in this study. It does not support the broader claim that retatrutide has been proven to cure all forms or stages of metabolic liver disease.

3. Retatrutide Can Produce Major Improvements in Glucose Control

Retatrutide has also been studied directly in adults with type 2 diabetes. A Phase 2 randomized trial involving 281 participants found substantial reductions in both HbA1c and body weight at higher retatrutide doses compared with placebo. [4]

Phase 3 research has since expanded this evidence. In 2026, Lilly reported additional trial results showing substantial improvements in glycemic control alongside major reductions in body weight. In TRIUMPH-2, which enrolled adults with obesity or overweight and type 2 diabetes, the 12 mg group reportedly lost an average of 49.6 pounds, or 20.8% of starting body weight, over 80 weeks. Average HbA1c reduction in that group was approximately 1.5 percentage points. [6]

This matters because participants with type 2 diabetes often experience somewhat smaller average weight reductions in obesity-drug trials than people without diabetes. Retatrutide still produced substantial changes in both weight and glucose control in that population.

The important lesson is that retatrutide’s clinical profile is not limited to body weight. It is influencing multiple metabolic outcomes simultaneously.

THREE THINGS RESEARCH HAS NOT PROVEN

1. Retatrutide Has Not Been Proven to Preserve Muscle

One of the most persistent claims surrounding retatrutide is that its triple-receptor mechanism somehow allows people to lose large amounts of fat while preserving skeletal muscle. The human evidence is more complicated.

A prespecified body-composition substudy published in The Lancet Diabetes & Endocrinology used DXA scanning to examine changes in fat mass and lean mass in participants with type 2 diabetes. Researchers observed large decreases in fat mass, but lean mass also declined. [7]

The encouraging finding was that the proportion of lean mass lost relative to total body-weight reduction appeared broadly consistent with what has been observed with other major obesity treatments. In other words, retatrutide’s unusually large overall weight reduction did not appear to produce a disproportionately large share of lean-mass loss.

That is useful evidence, but it is not the same as proving that retatrutide uniquely protects skeletal muscle.

There is another important limitation in how these findings are discussed. DXA measures lean mass, not skeletal muscle alone. Lean mass includes muscle, water, organs, connective tissue and other fat-free components. Turning a DXA lean-mass value directly into a statement about pounds of muscle lost oversimplifies what the measurement actually represents.

At this stage, the evidence is more accurately summarized by saying that retatrutide has not shown obviously disproportionate lean-mass loss relative to total weight reduction. That is substantially different from claiming that it has been proven to preserve muscle.

2. Human Research Has Not Yet Shown Exactly How Much Retatrutide Raises Energy Expenditure

The glucagon component of retatrutide is one of the main reasons the molecule attracts so much scientific interest. A simplified explanation often appears online: GLP-1 reduces appetite, GIP improves metabolic signalling, glucagon raises energy expenditure, and retatrutide therefore causes greater weight loss by making someone eat less while also making them burn substantially more calories.

There is legitimate biology underneath that idea. Preclinical work supports a role for glucagon-receptor activation in increasing energy expenditure with retatrutide. However, the major human obesity trials were not designed primarily to measure exactly how many additional calories participants expended each day because of glucagon-receptor activity.

They were designed to measure clinical outcomes such as body weight, waist circumference, glucose, liver fat, lipids and adverse events.

The human outcome is therefore much more firmly established than the precise mechanism. Researchers know that people lost large amounts of weight. They do not yet have a simple human number that tells them how much of that reduction resulted from decreased food intake and how much resulted from increased energy expenditure.

That distinction is important because it lies at the centre of what may make triple agonism different from earlier incretin therapies. If future metabolic-chamber or tracer studies can quantify the independent contribution of glucagon-related energy expenditure, researchers may be able to explain more clearly why retatrutide produces the magnitude of weight change observed in clinical trials.

3. Retatrutide Has Not Yet Proven It Is the “Best” Metabolic Therapy

The size of the retatrutide weight-loss results naturally invites comparisons with semaglutide, tirzepatide and even bariatric surgery. However, placing headline numbers from separate clinical trials side by side does not prove superiority.

Different studies enroll different populations, use different durations, apply different dose-escalation schedules, use different statistical methods and have different discontinuation rates. Some include participants with diabetes, while others do not. Background lifestyle interventions also vary.

Indirect comparisons can be useful, but they are not equivalent to a head-to-head randomized clinical trial.

That is beginning to change. TRANSCEND-T2D-2 is directly comparing retatrutide with semaglutide in adults with type 2 diabetes, with an estimated enrollment of approximately 1,250 participants. [8] Results from direct trials like this will provide much stronger evidence about comparative effectiveness than separate headline numbers ever can.

Even then, superiority in body-weight reduction would answer only one question. Cardiovascular outcomes, kidney outcomes, tolerability, treatment persistence, glycemic control, quality of life and long-term safety all matter.

A treatment can produce the greatest weight reduction and still require additional evidence before it can be described as the best overall therapy.